金斯瑞与中国药科大学共建大学生实训基地 助力生物科技后备人才培养

2020-09-10 佚名 医谷网

9月9日,金斯瑞与中国药科大学实训基地签约及产学研合作正式启动,双方将围绕本科生实习、研究生联合培养以及实际案例的教材编写等方面共建大学生实训基地。此次实训基地的建立,是金斯瑞在探索产教融合、进一步提

9月9日,金斯瑞与中国药科大学实训基地签约及产学研合作正式启动,双方将围绕本科生实习、研究生联合培养以及实际案例的教材编写等方面共建大学生实训基地。此次实训基地的建立,是金斯瑞在探索产教融合、进一步提升校企合作层次的重要里程碑事件,旨在运用金斯瑞自身的产业平台力量,助力高校提高教学质量和科研水平、提升科研创新能力,并培养和提升学生实践能力、塑造其创新创业思维与意识,为生物医药产业不断培养后续人才。此外,这也是金斯瑞积极响应国家关于产教融合等一系列政策,“充分发挥企业在技术技能人才培养和人力资源开发中的重要主体作用、强化产教融合型企业的带动引领示范作用”方面的重要举措。

金斯瑞集团欧洲地区部总裁邵炜慧、人力资源副总裁吴盛、企业传播与政府事务副总裁陈曦与中国药科大学教务处处长唐伟方、副处长江程、生命科学与技术学院党委书记高向东、生命科学与技术学院院长王琛、副院长刘煜等校企领导和代表出席了会议。在全面战略合作的背景下,双方也就双创导师培养、科研成果转化及科学实验室共建的产学研战略合作模式、深化专业和产业相互促进、共同发展,以及实现“校企合作、产学共赢”等话题进行了深入探讨。

金斯瑞集团欧洲地区部总裁邵炜慧表示,随着业务领域的不断拓展,金斯瑞期望更多的优秀人才加入金斯瑞。此次与中国药科大学签订包括实训基地、研究生联合培养以及产学研深度合作的框架协议,可以很好的实现校企产教资源的优势互补,搭建生物科技领域人才培养新通道。对于下一步的合作规划,应充分发挥学校和企业的各自优势,全面深化在实验室、科研项目、研发设备等方面的共建共享。

中国药科大学教务处处长唐伟方表示,中国药科大学是一所历史悠久、在药学界享有盛誉的高校,坚持“学术第一、师生为本、共生共赢”的理念,培养造就药界英才。此次和金斯瑞的合作,是药科大在生物科学领域人才培养的又一尝试与探索,相信金斯瑞成立18年以来积累的行业优势和领先科技,可以为药科大的学生提供更多学习、发现、实践的平台。

作为全球化的生物科技集团公司,金斯瑞一直十分注重对人才的投入。目前,金斯瑞在全球拥有超过3900名员工,其中36%以上的员工拥有博士或硕士学位。在自身发展的同时,金斯瑞始终注重对行业高精尖人才的培养,截至目前,已与15所高校签订校企合作协议。特别是今年,因受疫情影响,在高校学生实习、就业均面临较大困难的情况下,金斯瑞与7所院校签订了校企合作协议,并为2020届及2021届毕业生提供了超过550个就业和实习机会。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2005234, encodeId=f59b20052340d, content=<a href='/topic/show?id=3b8b6941646' target=_blank style='color:#2F92EE;'>#生物科技#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69416, encryptionId=3b8b6941646, topicName=生物科技)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71f1477, createdName=s_pl2008, createdTime=Fri Sep 18 06:30:50 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649747, encodeId=f49b1649e477f, content=<a href='/topic/show?id=4a8b220090b' target=_blank style='color:#2F92EE;'>#中国药科大学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22009, encryptionId=4a8b220090b, topicName=中国药科大学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e4823916450, createdName=yzh407, createdTime=Tue Jan 12 06:30:50 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910105, encodeId=48091910105c8, content=<a href='/topic/show?id=21574368886' target=_blank style='color:#2F92EE;'>#大学生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43688, encryptionId=21574368886, topicName=大学生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3883266, createdName=yykkxiaodou, createdTime=Sun Oct 11 10:30:50 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516501, encodeId=1aa3151650184, content=<a href='/topic/show?id=a6ba96195c5' target=_blank style='color:#2F92EE;'>#金斯瑞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96195, encryptionId=a6ba96195c5, topicName=金斯瑞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f12410973048, createdName=12498da4m35(暂无昵称), createdTime=Sat Sep 12 14:30:50 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554893, encodeId=b3b8155489382, content=<a href='/topic/show?id=023b249083e' target=_blank style='color:#2F92EE;'>#人才培养#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24908, encryptionId=023b249083e, topicName=人才培养)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=056914558248, createdName=jml2014, createdTime=Sat Sep 12 14:30:50 CST 2020, time=2020-09-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2005234, encodeId=f59b20052340d, content=<a href='/topic/show?id=3b8b6941646' target=_blank style='color:#2F92EE;'>#生物科技#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69416, encryptionId=3b8b6941646, topicName=生物科技)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71f1477, createdName=s_pl2008, createdTime=Fri Sep 18 06:30:50 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649747, encodeId=f49b1649e477f, content=<a href='/topic/show?id=4a8b220090b' target=_blank style='color:#2F92EE;'>#中国药科大学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22009, encryptionId=4a8b220090b, topicName=中国药科大学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e4823916450, createdName=yzh407, createdTime=Tue Jan 12 06:30:50 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910105, encodeId=48091910105c8, content=<a href='/topic/show?id=21574368886' target=_blank style='color:#2F92EE;'>#大学生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43688, encryptionId=21574368886, topicName=大学生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3883266, createdName=yykkxiaodou, createdTime=Sun Oct 11 10:30:50 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516501, encodeId=1aa3151650184, content=<a href='/topic/show?id=a6ba96195c5' target=_blank style='color:#2F92EE;'>#金斯瑞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96195, encryptionId=a6ba96195c5, topicName=金斯瑞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f12410973048, createdName=12498da4m35(暂无昵称), createdTime=Sat Sep 12 14:30:50 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554893, encodeId=b3b8155489382, content=<a href='/topic/show?id=023b249083e' target=_blank style='color:#2F92EE;'>#人才培养#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24908, encryptionId=023b249083e, topicName=人才培养)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=056914558248, createdName=jml2014, createdTime=Sat Sep 12 14:30:50 CST 2020, time=2020-09-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2005234, encodeId=f59b20052340d, content=<a href='/topic/show?id=3b8b6941646' target=_blank style='color:#2F92EE;'>#生物科技#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69416, encryptionId=3b8b6941646, topicName=生物科技)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71f1477, createdName=s_pl2008, createdTime=Fri Sep 18 06:30:50 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649747, encodeId=f49b1649e477f, content=<a href='/topic/show?id=4a8b220090b' target=_blank style='color:#2F92EE;'>#中国药科大学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22009, encryptionId=4a8b220090b, topicName=中国药科大学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e4823916450, createdName=yzh407, createdTime=Tue Jan 12 06:30:50 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910105, encodeId=48091910105c8, content=<a href='/topic/show?id=21574368886' target=_blank style='color:#2F92EE;'>#大学生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43688, encryptionId=21574368886, topicName=大学生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3883266, createdName=yykkxiaodou, createdTime=Sun Oct 11 10:30:50 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516501, encodeId=1aa3151650184, content=<a href='/topic/show?id=a6ba96195c5' target=_blank style='color:#2F92EE;'>#金斯瑞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96195, encryptionId=a6ba96195c5, topicName=金斯瑞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f12410973048, createdName=12498da4m35(暂无昵称), createdTime=Sat Sep 12 14:30:50 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554893, encodeId=b3b8155489382, content=<a href='/topic/show?id=023b249083e' target=_blank style='color:#2F92EE;'>#人才培养#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24908, encryptionId=023b249083e, topicName=人才培养)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=056914558248, createdName=jml2014, createdTime=Sat Sep 12 14:30:50 CST 2020, time=2020-09-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2005234, encodeId=f59b20052340d, content=<a href='/topic/show?id=3b8b6941646' target=_blank style='color:#2F92EE;'>#生物科技#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69416, encryptionId=3b8b6941646, topicName=生物科技)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71f1477, createdName=s_pl2008, createdTime=Fri Sep 18 06:30:50 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649747, encodeId=f49b1649e477f, content=<a href='/topic/show?id=4a8b220090b' target=_blank style='color:#2F92EE;'>#中国药科大学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22009, encryptionId=4a8b220090b, topicName=中国药科大学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e4823916450, createdName=yzh407, createdTime=Tue Jan 12 06:30:50 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910105, encodeId=48091910105c8, content=<a href='/topic/show?id=21574368886' target=_blank style='color:#2F92EE;'>#大学生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43688, encryptionId=21574368886, topicName=大学生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3883266, createdName=yykkxiaodou, createdTime=Sun Oct 11 10:30:50 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516501, encodeId=1aa3151650184, content=<a href='/topic/show?id=a6ba96195c5' target=_blank style='color:#2F92EE;'>#金斯瑞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96195, encryptionId=a6ba96195c5, topicName=金斯瑞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f12410973048, createdName=12498da4m35(暂无昵称), createdTime=Sat Sep 12 14:30:50 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554893, encodeId=b3b8155489382, content=<a href='/topic/show?id=023b249083e' target=_blank style='color:#2F92EE;'>#人才培养#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24908, encryptionId=023b249083e, topicName=人才培养)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=056914558248, createdName=jml2014, createdTime=Sat Sep 12 14:30:50 CST 2020, time=2020-09-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2005234, encodeId=f59b20052340d, content=<a href='/topic/show?id=3b8b6941646' target=_blank style='color:#2F92EE;'>#生物科技#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69416, encryptionId=3b8b6941646, topicName=生物科技)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71f1477, createdName=s_pl2008, createdTime=Fri Sep 18 06:30:50 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649747, encodeId=f49b1649e477f, content=<a href='/topic/show?id=4a8b220090b' target=_blank style='color:#2F92EE;'>#中国药科大学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22009, encryptionId=4a8b220090b, topicName=中国药科大学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e4823916450, createdName=yzh407, createdTime=Tue Jan 12 06:30:50 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910105, encodeId=48091910105c8, content=<a href='/topic/show?id=21574368886' target=_blank style='color:#2F92EE;'>#大学生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43688, encryptionId=21574368886, topicName=大学生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3883266, createdName=yykkxiaodou, createdTime=Sun Oct 11 10:30:50 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516501, encodeId=1aa3151650184, content=<a href='/topic/show?id=a6ba96195c5' target=_blank style='color:#2F92EE;'>#金斯瑞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96195, encryptionId=a6ba96195c5, topicName=金斯瑞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f12410973048, createdName=12498da4m35(暂无昵称), createdTime=Sat Sep 12 14:30:50 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554893, encodeId=b3b8155489382, content=<a href='/topic/show?id=023b249083e' target=_blank style='color:#2F92EE;'>#人才培养#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24908, encryptionId=023b249083e, topicName=人才培养)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=056914558248, createdName=jml2014, createdTime=Sat Sep 12 14:30:50 CST 2020, time=2020-09-12, status=1, ipAttribution=)]

相关资讯

Jonathan Rothberg:生物科技领域的史蒂夫•乔布斯

乔纳森·罗森伯格(Jonathan Rothberg)绝对堪称是生物界的风云人物。他早年分别获得卡内基梅隆大学的工学学士学位和耶鲁大学的分子生物化学博士学位、哲学博士学位,曾先后创立过五家健康和生物科学公司,为DNA测序技术的发展做出了重大贡献。且在过去七年间,他将自己创办的两家基因研究公司454 Life Sciences和Ion Torrent Syst以超过5亿美元的价格卖了出去,

生物科技前八名的亚洲国家,日本第二,中国排第几?

即使在衰退的一年中,亚洲的生物技术行业也超过了美国。正如EY年度“超越边界”报告最新一期所述,中国、日本、新加坡、韩国和台湾的生物科技业总共募集了超过25亿美元的融资。去年IPO市场萎缩以及公开交易的生物技术的后续融资和其他资金下降抵消了风险投资(VC)融资11%的增长。

Puma生物科技宣布neratinib“积极”临床结果

今天Puma生物科技宣布其乳腺癌药物neratinib在一个叫做NEFERTT 的二期临床实验中显示“积极”结果。这个实验比较neratinib+紫杉醇和赫赛汀+紫杉醇作为一线药物在复发未转移和已转移乳腺癌患者中的疗效和安全性。一级终点是无进展生存期,二级终点是客观应答率和中枢转移率。和对照组相比,neratinib组无进展生存期无差别(分别为16.6和16.7个月),应答率也无区别(74.8

港交所开启新时代 致力打造生物科技主要金融市场

五月第一天,登陆香港交易所官网,新闻头条“开启新时代”红色字样十分醒目。因为劳动节假日,香港交易所旗下市场于5月1日休市。微信图片_20180501142616.png香港交易所官方网站截图4月30日,港交所正式接受同股不同权新经济公司、无营收的生物科技公司申请。港交所行政总裁李小加预期,很快有不下10家按新例提交上市申请,首批可于6月或7月上市。4月24日,港交所公布“引入同股不同权机制及生